Caryle via their specialist life sciences arm invested $170M USD into OPT after 9 months of due diligence (they only invest in 2-3 deals a year after assessing 100s). These are specialist investors and have much more biotech knowledge than 99% brokers / ppl on HC. Always DYOR but accept that these guys know what they are doing.
Add to My Watchlist
What is My Watchlist?